NBIX
$133.4
Revenue | $572.6Mn |
Net Profits | $7.9Mn |
Net Profit Margins | 1.38% |
PE Ratio | 45.71 |
Neurocrine Biosciences Inc.’s revenue jumped 11.12% since last year same period to $572.6Mn in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -8.78% fall in its revenue since last 3-months.
Neurocrine Biosciences Inc.’s net profit fell -81.8% since last year same period to $7.9Mn in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -92.34% fall in its net profits since last 3-months.
Neurocrine Biosciences Inc.’s net profit margin fell -83.62% since last year same period to 1.38% in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -91.6% fall in its net profit margins since last 3-months.
Neurocrine Biosciences Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 45.71.
EPS Estimate Current Quarter | 1.39 |
EPS Estimate Current Year | 1.39 |
Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.39 - a 42.07% jump from last quarter’s estimates.
Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current year stand at 1.39.
Earning Per Share (EPS) | 0 |
Neurocrine Biosciences Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Neurocrine Biosciences Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-05-05 | 1.09 | 0.7 | -36.02% |
2025-11-04 | 1.39 | 0 | -100% |